•
Mar 31, 2021
Design Therapeutics Q1 2021 Earnings Report
Reported first quarter 2021 financial results and provided business highlights.
Key Takeaways
Design Therapeutics reported a net loss of $5.5 million for the first quarter ended March 31, 2021. The company successfully completed a $276 million IPO and is on track to initiate a Phase 1 clinical trial for Friedreich Ataxia in the first half of 2022.
On-track with Clinical Development Plans for Friedreich Ataxia Program Following Pre-IND Meeting with FDA.
Myotonic Dystrophy Type-1 Program Advancing as Planned.
Successfully completed a $276 Million Initial Public Offering (IPO).
Reported cash, cash equivalents and investment securities of $411.3 million.
Design Therapeutics
Design Therapeutics
Forward Guidance
The company is focused on advancing its GeneTAC platform and initiating a Phase 1 clinical trial for Friedreich Ataxia in the first half of 2022.